• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

人源移植瘤免疫动力学在肿瘤免疫治疗中的应用

Immunodynamics of explanted human tumors for immuno-oncology.

机构信息

Institut Gustave Roussy, Villejuif, France.

Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.

出版信息

EMBO Mol Med. 2021 Jan 11;13(1):e12850. doi: 10.15252/emmm.202012850. Epub 2020 Dec 29.

DOI:10.15252/emmm.202012850
PMID:33372722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7799366/
Abstract

Decision making in immuno-oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno-assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This "in sitro" (in situ/in vitro) assay has the potential to predict unresponsiveness to anti-PD-1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.

摘要

免疫肿瘤学中的决策对于根据患者肿瘤微环境（TME）选择众多单克隆抗体或小分子药物的治疗方案至关重要。预测最佳联合治疗方案仍然是一个未满足的医疗需求。在这里，我们报告了一种基于 TME 对十二种免疫调节剂（包括免疫检查点抑制剂（ICI））的体外刺激反应能力的多功能和动态免疫分析方法，该方法在 43 个人类原发性肿瘤中进行。这种“原位”（in situ/in vitro）分析方法有可能预测对抗 PD-1 mAb 的无反应性，并检测最合适和个性化的联合治疗方案。期待进行前瞻性临床试验来验证这种原位分析方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/a250c6a371ea/EMMM-13-e12850-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/65f6001160f9/EMMM-13-e12850-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/db8872587613/EMMM-13-e12850-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/402326d11a41/EMMM-13-e12850-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/924b45e0b3bd/EMMM-13-e12850-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/3903d5687ecf/EMMM-13-e12850-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/ddd8f80331f8/EMMM-13-e12850-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/a250c6a371ea/EMMM-13-e12850-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/65f6001160f9/EMMM-13-e12850-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/db8872587613/EMMM-13-e12850-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/402326d11a41/EMMM-13-e12850-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/924b45e0b3bd/EMMM-13-e12850-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/3903d5687ecf/EMMM-13-e12850-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/ddd8f80331f8/EMMM-13-e12850-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a2/7799366/a250c6a371ea/EMMM-13-e12850-g008.jpg

相似文献

1
Immunodynamics of explanted human tumors for immuno-oncology.人源移植瘤免疫动力学在肿瘤免疫治疗中的应用
EMBO Mol Med. 2021 Jan 11;13(1):e12850. doi: 10.15252/emmm.202012850. Epub 2020 Dec 29.
2
An In Sitro Assay to Predict Primary Resistance to PD-1 Blockade.一种预测 PD-1 阻断原发性耐药的体外检测方法。
Trends Mol Med. 2021 Apr;27(4):297-298. doi: 10.1016/j.molmed.2021.01.006. Epub 2021 Jan 29.
3
Personalized Immuno-Oncology.个性化免疫肿瘤学。
Med Princ Pract. 2021;30(1):1-16. doi: 10.1159/000511107. Epub 2020 Aug 25.
4
New Immuno-oncology Targets and Resistance Mechanisms.新型免疫肿瘤学靶点和耐药机制。
Curr Treat Options Oncol. 2022 Sep;23(9):1201-1218. doi: 10.1007/s11864-022-01005-8. Epub 2022 Aug 18.
5
Assessment of IFN-γ and granzyme-B production by in "sitro" technology.采用“原位”技术评估 IFN-γ 和 granzyme-B 的产生。
Methods Enzymol. 2020;631:391-414. doi: 10.1016/bs.mie.2019.08.001. Epub 2019 Oct 18.
6
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).个性化医学和肿瘤免疫时代临床试验的变化：国际肿瘤学和血液肿瘤学临床试验大会（ICTO 2017）报告。
J Exp Clin Cancer Res. 2017 Dec 28;36(1):192. doi: 10.1186/s13046-017-0668-0.
7
Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.肿瘤微环境中的新兴免疫检查点：对癌症免疫治疗的影响。
Cancer Lett. 2021 Jul 28;511:68-76. doi: 10.1016/j.canlet.2021.04.021. Epub 2021 May 3.
8
Leveraging NKG2D Ligands in Immuno-Oncology.利用免疫肿瘤学中的 NKG2D 配体。
Front Immunol. 2021 Jul 29;12:713158. doi: 10.3389/fimmu.2021.713158. eCollection 2021.
9
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.外周驱动的髓系 NFkB 和 IFN/ISG 反应可预测卵巢癌的恶性风险、生存和免疫治疗方案。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003609.
10
In Vivo Modeling of Tumor Heterogeneity for Immuno-Oncology Studies: Failures, Improvements, and Hopes.肿瘤异质性的免疫肿瘤学研究体内建模：失败、改进和希望。
Curr Protoc. 2022 Mar;2(3):e377. doi: 10.1002/cpz1.377.

引用本文的文献

1
Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors.用于犬乳腺肿瘤诊断和预后预测的血清自身抗体生物标志物 panel 的多重免疫分析
Vet Q. 2025 Dec;45(1):1-12. doi: 10.1080/01652176.2024.2435978. Epub 2024 Dec 6.
2
Immune checkpoints are predominantly co-expressed by clonally expanded CD4FoxP3 intratumoral T-cells in primary human cancers.免疫检查点主要由原发性人类癌症中克隆扩增的 CD4FoxP3 肿瘤内 T 细胞共表达。
J Exp Clin Cancer Res. 2023 Dec 6;42(1):333. doi: 10.1186/s13046-023-02897-6.
3
Fusing WGCNA and Machine Learning for Immune-Related Gene Prognostic Index in Lung Adenocarcinoma: Precision Prognosis, Tumor Microenvironment Profiling, and Biomarker Discovery.

本文引用的文献

1
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.血清白细胞介素-8 水平升高与肿瘤内中性粒细胞增多和免疫检查点抑制剂临床获益降低有关。
Nat Med. 2020 May;26(5):688-692. doi: 10.1038/s41591-020-0856-x. Epub 2020 May 11.
2
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells.肿瘤异质性和克隆合作影响 IFN-γ 信号突变癌细胞的免疫选择。
Nat Commun. 2020 Jan 30;11(1):602. doi: 10.1038/s41467-020-14290-4.
3
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
融合加权基因共表达网络分析（WGCNA）和机器学习构建肺腺癌免疫相关基因预后指数：精准预后、肿瘤微环境剖析及生物标志物发现
J Inflamm Res. 2023 Nov 16;16:5309-5326. doi: 10.2147/JIR.S436431. eCollection 2023.
4
Development of a salivary autoantibody biomarker panel for diagnosis of oral cavity squamous cell carcinoma.用于诊断口腔鳞状细胞癌的唾液自身抗体生物标志物组合的开发。
Front Oncol. 2022 Oct 31;12:968570. doi: 10.3389/fonc.2022.968570. eCollection 2022.
5
Charting roadmaps towards novel and safe synergistic immunotherapy combinations.绘制新颖且安全的协同免疫治疗组合的路线图。
Nat Cancer. 2022 Jun;3(6):665-680. doi: 10.1038/s43018-022-00401-1. Epub 2022 Jun 28.
6
Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8 T cells.肿瘤来源的 IL-8 通过 PD-1 在 CD8 T 细胞中的上调促进胃癌的淋巴结转移。
Cancer Immunol Immunother. 2022 Dec;71(12):3057-3070. doi: 10.1007/s00262-022-03223-3. Epub 2022 May 28.
7
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.靶向 PD-L1 和 TIGIT 可恢复人类结直肠癌肿瘤内 CD8 T 细胞功能。
Cancer Immunol Immunother. 2022 Oct;71(10):2549-2563. doi: 10.1007/s00262-022-03182-9. Epub 2022 Mar 16.
8
Targeting the DNA damage response in immuno-oncology: developments and opportunities.靶向免疫肿瘤学中的 DNA 损伤反应：进展与机遇。
Nat Rev Cancer. 2021 Nov;21(11):701-717. doi: 10.1038/s41568-021-00386-6. Epub 2021 Aug 10.
T 细胞受体库的空间异质性反映了肺癌中的突变景观。
Nat Med. 2019 Oct;25(10):1549-1559. doi: 10.1038/s41591-019-0592-2. Epub 2019 Oct 7.
4
Tumour-intrinsic resistance to immune checkpoint blockade.肿瘤内在的免疫检查点阻断耐药性。
Nat Rev Immunol. 2020 Jan;20(1):25-39. doi: 10.1038/s41577-019-0218-4. Epub 2019 Sep 30.
5
PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.PD-1 阻断扩增的 PD-1 调节性 T 细胞促进癌症的过度进展。
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. doi: 10.1073/pnas.1822001116. Epub 2019 Apr 26.
6
Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers.肾细胞癌 (RCC) 肿瘤表现出大量表达衰竭标志物的双阳性 (DP) CD4+CD8+T 细胞的扩增。
Front Immunol. 2018 Nov 26;9:2728. doi: 10.3389/fimmu.2018.02728. eCollection 2018.
7
Hyperprogressive disease: recognizing a novel pattern to improve patient management.Hyperprogressive disease：认识一种新的模式以改善患者管理。
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762. doi: 10.1038/s41571-018-0111-2.
8
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.免疫检查点阻断治疗的基本机制。
Cancer Discov. 2018 Sep;8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367. Epub 2018 Aug 16.
9
A transcriptionally and functionally distinct PD-1 CD8 T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.PD-1 阻断治疗非小细胞肺癌中具有预测潜力的转录和功能不同的 PD-1 CD8 T 细胞池。
Nat Med. 2018 Jul;24(7):994-1004. doi: 10.1038/s41591-018-0057-z. Epub 2018 Jun 11.
10
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.Fc 效应功能有助于人类抗 CTLA-4 抗体的活性。
Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22.